{"entity":{"id":"nct06502977","kind":"trial","name":"Study Evaluating Tarlatamab in Chinese Participants With Advanced Small Cell Lung Cancer After Two or More Prior Lines of Treatment","aka":["DeLLphi-307"],"tldr":"A phase 2 trial of Tarlatamab in small-cell lung cancer, run by Amgen, active and no longer recruiting.","summary":"Study Evaluating Tarlatamab in Chinese Participants With Advanced Small Cell Lung Cancer After Two or More Prior Lines of Treatment is a phase 2 interventional study registered as NCT06502977 by Amgen, with 32 participants enrolled, started 2024-08-27 and due to reach its primary completion in 2025-03-28. Interventions recorded: Tarlatamab. Conditions listed: Extensive Stage Small Cell Lung Cancer. Results were posted on ClinicalTrials.gov in 2026; the figures recorded here are the registry's, not a publication's.","status":"active","asOf":"2026-09-22","links":[{"label":"ClinicalTrials.gov NCT06502977","url":"https://clinicaltrials.gov/study/NCT06502977"}],"tags":["ctgov-ingest"],"related":[],"cancers":["sclc"],"sections":[],"technologies":["t-cell-engager"],"targets":[],"drugs":["tarlatamab"],"companies":["amgen"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT06502977","phase":"2","setting":"Phase 2a Study Evaluating the Efficacy, Safety, Tolerability and Pharmacokinetics of Tarlatamab in Chinese Subjects With Advanced Small Cell Lung Cancer After Two or More Prior Lines of Treatment (DeLLphi-307)","sponsor":"Amgen","started":"2024-08-27","startedType":"actual","yearReported":2026,"enrolled":32,"enrolledBasis":"registry","outcomes":[{"endpoint":"Objective Response Rate (ORR) Based on Blinded Independent Central Review (BICR) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1)","primary":true,"unit":"%","arms":[{"name":"Tarlatamab","n":31,"value":38.7,"note":"95% CI 21.8 to 57.8; Figures from the ClinicalTrials.gov results section (first posted 2026-04-15), not from a publication"}],"source":"https://clinicaltrials.gov/study/NCT06502977?tab=results"}]},"route":"/trials/nct06502977/","neighbours":{"cancer":[{"id":"sclc","kind":"cancer","name":"Small-cell lung cancer","route":"/cancers/sclc/"}],"technology":[{"id":"t-cell-engager","kind":"technology","name":"T-cell engagers (bispecific)","route":"/technologies/t-cell-engager/"}],"drug":[{"id":"tarlatamab","kind":"drug","name":"Tarlatamab","route":"/drugs/tarlatamab/"}],"company":[{"id":"amgen","kind":"company","name":"Amgen","route":"/companies/amgen/"}]}}